CancerDrs

Lymphoma clinical trials in Vermont

5 actively recruiting lymphoma trials at 3 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Vermont:
  • University of Vermont and State Agricultural College — Burlington, Vermont
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Vermont:
  • University of Vermont and State Agricultural College — Burlington, Vermont
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Vermont:
  • Dartmouth Cancer Center - North — Saint Johnsbury, Vermont
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete resp…

Sponsor: Providence Health & Services
NCT ID: NCT06175000
Sites in Vermont:
  • University of Vermont — Burlington, Vermont
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Vermont:
  • Central Vermont Medical Center — Berlin Corners, Vermont
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07